125 related articles for article (PubMed ID: 2458308)
41. Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C.
Mosnier JF; Scoazec JY; Marcellin P; Degott C; Benhamou JP; Feldmann G
Gastroenterology; 1994 Nov; 107(5):1457-68. PubMed ID: 7523228
[TBL] [Abstract][Full Text] [Related]
42. Nature, pathogenesis and significance of the Mallory body.
French SW
Semin Liver Dis; 1981 Aug; 1(3):217-31. PubMed ID: 7051303
[No Abstract] [Full Text] [Related]
43. Immunoexpression of intermediate filaments and morphological changes in the liver and bile duct of rats infected with Fasciola hepatica.
Kolodziejczyk L; Laszczyńska M; Masiuk M; Grabowska M; Skrzydlewska E
Biotech Histochem; 2015; 90(7):477-85. PubMed ID: 25923046
[TBL] [Abstract][Full Text] [Related]
44. Vitamin A deficiency associated with enhanced proliferation of bile duct epithelial cells in the rat.
Weiss B; Barshack I; Onaca N; Goldberg I; Berkovich Z; Melzer E; Jonas A; Reifen R
Isr Med Assoc J; 2010 Feb; 12(2):82-6. PubMed ID: 20550030
[TBL] [Abstract][Full Text] [Related]
45. Development of intrahepatic bile ducts in humans. Immunohistochemical study using monoclonal cytokeratin antibodies.
Shah KD; Gerber MA
Arch Pathol Lab Med; 1989 Oct; 113(10):1135-8. PubMed ID: 2478106
[TBL] [Abstract][Full Text] [Related]
46. [Hepatic neoductules].
Fischer HP; Meybehm M; Zhou H; Schoch J
Verh Dtsch Ges Pathol; 1995; 79():36-46. PubMed ID: 8600693
[TBL] [Abstract][Full Text] [Related]
47. A cytokeratin immunohistochemical study of cholestatic liver disease: evidence that hepatocytes can express 'bile duct-type' cytokeratins.
Van Eyken P; Sciot R; Desmet VJ
Histopathology; 1989 Aug; 15(2):125-35. PubMed ID: 2476370
[TBL] [Abstract][Full Text] [Related]
48. Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen.
Ueno T; Inuzuka S; Torimura T; Oohira H; Ko H; Obata K; Sata M; Yoshida H; Tanikawa K
Scand J Gastroenterol; 1992 Jun; 27(6):513-20. PubMed ID: 1631498
[TBL] [Abstract][Full Text] [Related]
49. The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey).
Jensen K; Gluud C
Hepatology; 1994 Oct; 20(4 Pt 1):1061-77. PubMed ID: 7927209
[TBL] [Abstract][Full Text] [Related]
50. Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody.
Hazan R; Denk H; Franke WW; Lackinger E; Schiller DL
Lab Invest; 1986 May; 54(5):543-53. PubMed ID: 2422438
[TBL] [Abstract][Full Text] [Related]
51. Quantitative immunohistochemical analysis of lymphocyte subsets in alcoholic liver disease.
Sakai Y; Izumi N; Marumo F; Sato C
J Gastroenterol Hepatol; 1993; 8(1):39-43. PubMed ID: 8439661
[TBL] [Abstract][Full Text] [Related]
52. Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis.
Spengler U; Pape GR; Hoffmann RM; Johnson JP; Eisenburg J; Paumgartner G; Riethmüller G
Hepatology; 1988; 8(3):459-62. PubMed ID: 3371866
[TBL] [Abstract][Full Text] [Related]
53. Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies.
Zatloukal K; Stumptner C; Lehner M; Denk H; Baribault H; Eshkind LG; Franke WW
Am J Pathol; 2000 Apr; 156(4):1263-74. PubMed ID: 10751352
[TBL] [Abstract][Full Text] [Related]
54. Transient expression of bile-duct-specific cytokeratin in fetal mouse hepatocytes.
Shiojiri N
Cell Tissue Res; 1994 Oct; 278(1):117-23. PubMed ID: 7525069
[TBL] [Abstract][Full Text] [Related]
55. Morphometric and immunohistochemical characterization of human liver regeneration.
Rubin EM; Martin AA; Thung SN; Gerber MA
Am J Pathol; 1995 Aug; 147(2):397-404. PubMed ID: 7639333
[TBL] [Abstract][Full Text] [Related]
56. Hepatic overexpression of MHC class II antigens and macrophage-associated antigens (CD68) in patients with biliary atresia of poor prognosis.
Kobayashi H; Puri P; O'Briain DS; Surana R; Miyano T
J Pediatr Surg; 1997 Apr; 32(4):590-3. PubMed ID: 9126761
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody.
Barbatis C; Woods J; Morton JA; Fleming KA; McMichael A; McGee JO
Gut; 1981 Dec; 22(12):985-91. PubMed ID: 7033057
[TBL] [Abstract][Full Text] [Related]
58. Proteasome inhibition induces cytokeratin accumulation in vivo.
Bardag-Gorce F; Vu J; Nan L; Riley N; Li J; French SW
Exp Mol Pathol; 2004 Apr; 76(2):83-9. PubMed ID: 15010285
[TBL] [Abstract][Full Text] [Related]
59. Immune complex nephritis in alcoholic cirrhosis: detection of Mallory body antigen in complexes by means of monoclonal antibodies to Mallory bodies.
Burns J; D'Ardenne AJ; Morton JA; McGee JO
J Clin Pathol; 1983 Jul; 36(7):751-5. PubMed ID: 6306057
[TBL] [Abstract][Full Text] [Related]
60. Appearance of hepatocytelike cells in the interlobular bile ducts of human liver in various liver disease states.
Nomoto M; Uchikosi Y; Kajikazawa N; Tanaka Y; Asakura H
Hepatology; 1992 Nov; 16(5):1199-205. PubMed ID: 1385291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
